Back to News
Jun 18, 2026 12:00 PM

Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline

Biogen Inc. (NASDAQ:BIIB) on Wednesday agreed to acquire private biotechnology company RayThera Inc. for up to $1 billion.

The company looks to further expand its immunology pipeline and broaden its reach into additional disease areas.

The deal includes an upfront payment to RayThera shareholders, with the majority of the consideration tied to future clinical and regulatory milestone achievements.

The transaction is expected to close in the third quarter of 2026.

Read Also:

Biogen's Base Is Declining, But 8 Pipeline Readouts Could Flip The Story

Acquisition Adds Early-Stage Immunology Assets

RayThera focuses on discovering and developing small-molecule therapies for immunological ...